title: MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation.
abstract: Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the Philadelphia chromosome as the sole genetic abnormality and the accumulation of mature cells in peripheral blood into blast crisis, which is characterized by the rapid expansion of myeloid- or lymphoid-differentiation-arrested blast cells. Although ample studies have been conducted on the disease progress mechanisms, the underlying molecular mechanisms of the malignant phenotype transition are still unclear. In this study, we have shown that myofibrillogenesis regulator-1 (MR-1) was overexpressed in blast crisis patients and leukemic cells, but there was little trace expressed in healthy individuals and in most patients in CML chronic phase. MR-1 could inhibit the differentiation of myeloid cells into megakaryocytic lineages and accelerate cell proliferation. The molecular mechanism responsible for these effects was the interaction of MR-1 with MEK, which blocked the MEK/ERK signaling pathway by dephosphorylating MEK. Our results provide compelling and important evidence that MR-1 might act as a diagnostic marker and potential target of CML progression from chronic phase to blast crisis.
authors.affiliation: Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: W
authors.initials: W
authors.lastname: Zhao
authors.forename: H
authors.initials: H
authors.lastname: He
authors.forename: K
authors.initials: K
authors.lastname: Ren
authors.forename: B
authors.initials: B
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.forename: R-G
authors.initials: RG
authors.lastname: Shao
references.citation: Leukemia. 1987 Jun;1(6):524-5
references.pmid: 2444834
references.citation: J Thromb Haemost. 2010 Jan;8(1):17-26
references.pmid: 19874462
references.citation: Blood. 2001 May 1;97(9):2587-95
references.pmid: 11313246
references.citation: Acta Biochim Biophys Sin (Shanghai). 2004 Jun;36(6):412-8
references.pmid: 15188056
references.citation: Blood. 2006 May 15;107(10):3868-75
references.pmid: 16434494
references.citation: Mol Cell Biochem. 2004 Mar;258(1-2):25-33
references.pmid: 15030167
references.citation: Gene. 2002 Oct 16;299(1-2):35-55
references.pmid: 12459251
references.citation: Nature. 2010 Mar 18;464(7287):427-30
references.pmid: 20179705
references.citation: Trends Cell Biol. 2003 Feb;13(2):65-70
references.pmid: 12559756
references.citation: Blood. 1997 Nov 1;90(9):3462-70
references.pmid: 9345030
references.citation: Blood. 1984 Apr;63(4):789-99
references.pmid: 6584184
references.citation: Exp Cell Res. 1998 Feb 1;238(2):407-14
references.pmid: 9473349
references.citation: Mol Cell Biol. 1997 Apr;17(4):1947-58
references.pmid: 9121442
references.citation: Cancer Biol Ther. 2008 Jul;7(7):1073-8
references.pmid: 18437054
references.citation: J Clin Invest. 1990 Apr;85(4):1072-84
references.pmid: 2318965
references.citation: Methods Mol Biol. 2004;272:309-22
references.pmid: 15226553
references.citation: Blood. 1985 Dec;66(6):1384-92
references.pmid: 2998511
references.citation: Blood. 1998 May 15;91(10):3711-23
references.pmid: 9573008
references.citation: J Biol Chem. 2010 Jul 2;285(27):20595-606
references.pmid: 20442406
references.citation: Toxicol In Vitro. 2008 Sep;22(6):1503-10
references.pmid: 18586450
references.citation: Exp Hematol. 1987 Sep;15(8):822-32
references.pmid: 3476310
references.citation: J Clin Invest. 2007 Sep;117(9):2672-83
references.pmid: 17717601
references.citation: J Biol Chem. 1997 Sep 12;272(37):23366-70
references.pmid: 9287350
references.citation: Blood. 2004 Oct 15;104(8):2514-22
references.pmid: 15226183
references.citation: Oncogene. 1999 May 20;18(20):3085-97
references.pmid: 10340380
references.citation: Leukemia. 2003 Sep;17(9):1765-82
references.pmid: 12970777
references.citation: Ann Hematol. 2001 May;80(5):284-91
references.pmid: 11446731
references.citation: Blood. 1999 May 1;93(9):2876-83
references.pmid: 10216082
references.citation: Oncogene. 2012 Jul 12;31(28):3381-91
references.pmid: 22105363
references.citation: Autophagy. 2009 Nov;5(8):1092-8
references.pmid: 19786835
references.citation: Blood. 2004 Jun 1;103(11):4010-22
references.pmid: 14982876
references.citation: BMC Cancer. 2011 Jun 25;11:270
references.pmid: 21702971
references.citation: Cytometry. 1985 Nov;6(6):591-6
references.pmid: 2415311
references.citation: Blood. 1995 Jul 1;86(1):294-304
references.pmid: 7795236
references.citation: Int J Cancer. 1976 Oct 15;18(4):421-31
references.pmid: 789258
references.citation: Br J Haematol. 1997 Jan;96(1):111-6
references.pmid: 9012696
references.citation: J Biol Chem. 2008 Dec 19;283(51):35598-605
references.pmid: 18948272
references.citation: Hematology Am Soc Hematol Educ Program. 2007;:384-91
references.pmid: 18024655